P13569 (CFTR_HUMAN) Homo sapiens (Human)
Cystic fibrosis transmembrane conductance regulator UniProtKBInterProSTRINGInteractive Modelling
Available Structures
52 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| The complex of phosphorylated human delta F508 cystic fibrosis transmembrane conductance regulator … |
Heteromer | 100.0 | 2×MG; 2×ATP; 1×CLR; 1×D12; 1×VX8; 1×WJX; | |||
| Complex of human cystic fibrosis transmembrane conductance regulator (CFTR) and Z1834339853 |
Heteromer | 99.92 | 2×MG; 2×ATP; 5×POV; 1×ZRH; | |||
| Phosphorylated, ATP-bound human cystic fibrosis transmembrane conductance regulator (CFTR) |
Heteromer | 99.92 | 2×MG; 2×ATP; 5×POV; 1×CLR; | |||
| The complex of phosphorylated human cystic fibrosis transmembrane conductance regulator (CFTR) with… |
Heteromer | 99.92 | 2×MG; 2×ATP; 2×DD9; 4×D12; 2×CLR; 1×C14; 1×PJ8; 1×CV6; | |||
| The complex of phosphorylated human cystic fibrosis transmembrane conductance regulator (CFTR) with… |
Heteromer | 99.92 | 2×MG; 2×ATP; 1×D12; 2×D10; 3×CLR; 1×VX8; 1×UNX; | |||
| Complex of ivacaftor with cystic fibrosis transmembrane conductance regulator (CFTR) |
Heteromer | 99.92 | 2×MG; 2×ATP; 6×POV; 1×AJP; 1×VX7; | |||
| Complex of human cystic fibrosis transmembrane conductance regulator (CFTR) and GLPG1837 |
Heteromer | 99.92 | 1×LJP; 2×MG; 2×ATP; 5×POV; 1×CLR; | |||
| The complex of dephosphorylated human cystic fibrosis transmembrane conductance regulator (CFTR) an… |
Heteromer | 100.0 | 1×VX8; | |||
| Dephosphorylated, ATP-free human cystic fibrosis transmembrane conductance regulator (CFTR) |
Heteromer | 100.0 | ||||
| Human NBD1 of CFTR in complex with nanobodies D12 and T4 |
Heteromer | 100 | 2×MG; 1×ATP; | |||
| human NBD1 of CFTR in complex with nanobodies D12 and G3a |
Heteromer | 100 | 5×GLC; 6×ATP; 10×MG; 2×GOL; | |||
| Human NBD1 of CFTR in complex with nanobodies D12 and T8 |
Heteromer | 100.0 | 1×GOL; 1×MG; 1×ATP; | |||
| human NBD1 of CFTR in complex with nanobody G11a |
Heteromer | 98.14 | 1×ATP; 3×EDO; 1×GOL; | |||
| human NBD1 of CFTR in complex with nanobody T27 |
Heteromer | 97.86 | 2×ATP; | |||
| human NBD1 of CFTR in complex with nanobodies T2a and T4 |
Heteromer | 97.81 | 1×GOL; 1×PEG; | |||
| Crystal structure of human 14-3-3 gamma in complex with CFTR R-domain peptide pS768-pS795 |
Heteromer P61981; | 100.0 | ||||
| Crystal structure of human 14-3-3 protein beta in complex with CFTR peptide pS753pS768 and PPI stab… |
Heteromer S7N159; | 100.0 | 2×ARG; 2×Q95; 2×TYR; 2×GLN; | |||
| Crystal structure of human 14-3-3 zeta in complex with CFTR R-domain peptide pS753-pS768 and stabil… |
Heteromer P63104; | 100.0 | 1×FSC; | |||
| Crystal structure of human 14-3-3 zeta in complex with CFTR R-domain peptide pS753-pS768 |
Heteromer P63104; | 100.0 | 2×GLC; 4×CL; | |||
| Crystal structure of human 14-3-3 beta in complex with CFTR R-domain peptide pS753-pS768 |
Heteromer P31946; | 100.0 | 1×ETE; | |||
| Crystal structure of filamin-A immunoglobulin-like repeat 21 bound to an N-terminal peptide of CFTR |
Heteromer P21333; | 94.44 | ||||
| PDZ Domain of CAL (Cystic Fibrosis Transmembrane Regulator-Associated Ligand) |
Heteromer Q9HD26; | 100 | ||||
| Crystal structure of human F508A NBD1 domain with ATP | homo-5-mer | 98.13 | 5×MG; 5×ATP; | |||
| Complex of the phosphorylated human cystic fibrosis transmembrane conductance regulator (CFTR) with… | monomer | 99.91 | 2×MG; 2×ATP; 2×LBN; 2×CLR; 1×WG5; | |||
| The complex of phosphorylated human delta F508 cystic fibrosis transmembrane conductance regulator … | monomer | 100.0 | 2×MG; 2×ATP; 1×CLR; 1×D12; 1×VX7; 1×WJX; 1×CV6; | |||
| Phosphorylated, ATP-bound, inhibitor 172-bound E1371Q human cystic fibrosis transmembrane conductan… | monomer | 99.47 | 2×MG; 2×ATP; 5×POV; 1×CLR; 1×WG5; | |||
| Dephosphorylated human delta F508 cystic fibrosis transmembrane conductance regulator (CFTR) | monomer | 100.0 | ||||
| Dehosphorylated, ATP-bound human cystic fibrosis transmembrane conductance regulator (CFTR) | monomer | 98.35 | 2×MG; 2×ATP; | |||
| The complex of phosphorylated human delta F508 cystic fibrosis transmembrane conductance regulator … | monomer | 100.0 | 2×MG; 2×ATP; 1×CLR; 1×WJX; | |||
| Phosphorylated, ATP-bound, E1371Q human cystic fibrosis transmembrane conductance regulator (E1371Q… | monomer | 99.46 | 2×MG; 2×ATP; 5×POV; 1×CLR; | |||
| Human NBD1 with Phe508 | monomer | 98.03 | 1×MG; 1×ATP; | |||
| Crystal structure of human deltaF508 human NBD1 domain with ATP | monomer | 98.78 | 1×MG; 1×ATP; | |||
| Human deltaF508 NBD1 with three solubilizing mutations | monomer | 96.91 | 1×MG; 1×ATP; | |||
| Human CFTR aa389-678 (NBD1), deltaF508 with three solubilizing mutations, bound ATP | monomer | 98.0 | 1×ATP; 1×MG; | |||
| Human deltaF508 NBD1 with two solublizing mutations. | monomer | 97.89 | 1×MG; 1×ATP; | |||
| Minimal human CFTR first nucleotide binding domain as a head-to-tail dimer with delta F508 | monomer | 100.0 | 1×MG; 1×ATP; | |||
| Minimal human CFTR first nucleotide binding domain as a head-to-tail dimer | monomer | 100 | 1×MG; 1×ATP; | |||
| Minimal human CFTR first nucleotide binding domain as a monomer | monomer | 100 | 1×MG; 1×ATP; 1×GOL; | |||
| Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR)… | monomer | 100 | 1×TTP; 1×MG; | |||
| Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR)… | monomer | 100 | 1×MG; 1×GTP; | |||
| Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR)… | monomer | 100 | 1×MG; 1×DGT; | |||
| Human CFTR first nucleotide binding domain with dF508/V510D | monomer | 100 | 1×ATP; 1×MG; | |||
| Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR)… | monomer | 100 | 1×DUT; 1×MG; | |||
| Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR)… | monomer | 100 | 1×MG; 1×DTP; | |||
| Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR)… | monomer | 100 | 1×MG; 1×ATP; | |||
| Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR)… | monomer | 100 | 1×MG; 1×DCP; | |||
| Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR)… | monomer | 100 | 1×MG; 1×MGP; | |||
| Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR)… | monomer | 100 | 1×MG; 1×CTP; | |||
| Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR)… | monomer | 100 | 1×MG; 1×UTP; | |||
| Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR)… | monomer | 100 | 1×MG; 1×M5T; | |||
| Crystal structure of nucleotide-binding domain 2 (NBD2) of the human Cystic Fibrosis Transmembrane … | monomer | 96.51 | 1×ATP; 1×MG; | |||
| Crystal structure of human NBD2 complexed with N6-Phenylethyl-ATP (P-ATP) | monomer | 97.13 | 1×B44; | |||
3 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 9dw8.1.A | monomer | 0.67 | 2×B44; | 99.93 | ||
| 6d3r.1.A | monomer | 0.62 | 2×ATP; | 80.50 | ||
| 7svr.1.A | monomer | 0.62 | 1×VX8; | 100.00 | ||
4 SWISS-MODEL models built on isoform sequence
| Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|---|
| Isoform 2 | 8ubr.1.A | monomer | 0.65 | 1×MG; 1×ATP; 1×LBN; 2×CLR; 1×WG5; | 98.10 | ||
| Isoform 2 | 6d3r.1.A | monomer | 0.62 | 1×ATP; | 79.13 | ||
| Isoform 2 | 6ujt.1.A | monomer | 0.50 | 16.82 | |||
| Isoform 3 | 7sv7.1.A | monomer | 0.72 | 1×CLR; 1×CV6; | 98.67 | ||